Denali Therapeutics Inc
NASDAQ:DNLI
Denali Therapeutics Inc
NASDAQ:DNLI
Price:
18.9 USD
-1.61%
Market Closed
Updated:
May 29, 2024
Denali Therapeutics Inc
Other Current Liabilities
|
Denali Therapeutics Inc
Other Current Liabilities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Other Current Liabilities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Denali Therapeutics Inc
NASDAQ:DNLI
|
Other Current Liabilities
$12.5m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Current Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Current Liabilities
$3.3B
|
CAGR 3-Years
149%
|
CAGR 5-Years
406%
|
CAGR 10-Years
26%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Current Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Current Liabilities
$648.6m
|
CAGR 3-Years
32%
|
CAGR 5-Years
8%
|
CAGR 10-Years
27%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Current Liabilities
$516.7m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
23%
|
See Also
What is Denali Therapeutics Inc's Other Current Liabilities?
Other Current Liabilities
12.5m
USD
12.5m
USD
Based on the financial report for Mar 31, 2024, Denali Therapeutics Inc's Other Current Liabilities amounts to 12.5m USD.
What is Denali Therapeutics Inc's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
-12%
-12%
Over the last year, the Other Current Liabilities growth was -96%. The average annual Other Current Liabilities growth rates for Denali Therapeutics Inc have been -9% over the past three years , -12% over the past five years .
You don't have any saved screeners yet
